TALEN

TALEN1-nr1h3

ID

ZDB-TALEN-141208-1

Name

TALEN1-nr1h3

Previous Names

None

Target

nr1h3 (1)

Target Sequence 1

5' - GGCTTTCATTACAATGTGCT - 3'

Target Sequence 2

5' - GCGTCTGAAGAAACCTTT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
z101a	nr1h3
z102a	nr1h3

Expression

Gene expression in Wild Types + TALEN1-nr1h3

No data available

Phenotype

Phenotype resulting from TALEN1-nr1h3

No data available

Phenotype of all Fish created by or utilizing TALEN1-nr1h3

Phenotype	Fish	Conditions	Figures
male organism intestine fasn expression increased amount, abnormal	nr1h3^z101a/z101a	control	Fig. 5 from Benítez-Santana et al., 2017
male organism liver abca1a expression decreased amount, abnormal	nr1h3^z101a/z101a	control	Fig. 5 from Benítez-Santana et al., 2017
liver cholesteryl ester increased amount, abnormal	nr1h3^z101a/z101a	high cholesterol	Fig. 4 from Benítez-Santana et al., 2017
female organism lipoprotein lipase activity decreased process quality, abnormal	nr1h3^z101a/z101a	chemical treatment by injection: tyloxapol	Fig. 2 from Benítez-Santana et al., 2017
vasculature lipid increased amount, exacerbated	nr1h3^z101a/z101a	chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11	Fig. 1 from Benítez-Santana et al., 2017
female organism intestine srebf1 expression increased amount, abnormal	nr1h3^z101a/z101a	control	Fig. 5 from Benítez-Santana et al., 2017
liver cholesterol increased amount, abnormal	nr1h3^z101a/z101a	high cholesterol	Fig. 4 from Benítez-Santana et al., 2017
female organism intestine acaca expression increased amount, abnormal	nr1h3^z101a/z101a	control	Fig. 5 from Benítez-Santana et al., 2017
blood plasma cholesterol increased amount, exacerbated	nr1h3^z101a/z101a	high cholesterol	Fig. 3 from Benítez-Santana et al., 2017
blood plasma triglyceride increased amount, abnormal	nr1h3^z101a/z101a	chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11	Fig. 2 from Benítez-Santana et al., 2017
male organism intestine acaca expression decreased amount, abnormal	nr1h3^z101a/z101a	control	Fig. 5 from Benítez-Santana et al., 2017
male organism liver abca1b expression decreased amount, abnormal	nr1h3^z101a/z101a	control	Fig. 5 from Benítez-Santana et al., 2017
intestinal lipid absorption increased occurrence, abnormal	nr1h3^z101a/z101a	chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11	Fig. 1 from Benítez-Santana et al., 2017
male organism intestine srebf1 expression increased amount, abnormal	nr1h3^z101a/z101a	control	Fig. 5 from Benítez-Santana et al., 2017
male organism triglyceride increased amount, abnormal	nr1h3^z101a/z101a	chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11	Fig. 2 from Benítez-Santana et al., 2017
female organism liver abca1a expression decreased amount, abnormal	nr1h3^z101a/z101a	control	Fig. 5 from Benítez-Santana et al., 2017

Citations